Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bhattacharjee, Gargi | - |
dc.contributor.author | Gohil, Nisarg | - |
dc.contributor.author | Khambhati, Khushal | - |
dc.contributor.author | Mani, Indra | - |
dc.contributor.author | Maurya, Rupesh | - |
dc.contributor.author | Karapurkar, J.K. | - |
dc.contributor.author | Gohil, Janardhan | - |
dc.contributor.author | Chu, Dinh-Toi | - |
dc.contributor.author | Vu-Thi, H.ue | - |
dc.contributor.author | Alzahrani, Khalid J. | - |
dc.contributor.author | Show, Pau-Loke | - |
dc.contributor.author | Rawal, Rakesh M. | - |
dc.contributor.author | Ramakrishna, S. | - |
dc.contributor.author | Singh, Vijai | - |
dc.date.accessioned | 2022-07-06T08:42:46Z | - |
dc.date.available | 2022-07-06T08:42:46Z | - |
dc.date.created | 2022-03-07 | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/139349 | - |
dc.description.abstract | A single gene mutation can cause a number of human diseases that affect the quality of life. Until the development of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (Cas) systems, it was challenging to correct a gene mutation to avoid a disease by reverting phenotypes. The advent of CRISPR technology has changed the field of gene editing, given its simplicity and intrinsic programmability, surpassing the limitations of both zinc-finger nuclease and transcription activator-like effector nuclease and becoming the method of choice for therapeutic gene editing by overcoming the bottlenecks of conventional gene-editing techniques. Currently, there is no commercially available medicinal cure to correct a gene mutation that corrects and reverses the abnormality of a gene's function. Devising reprogramming strategies for faithful recapitulation of normal phenotypes is a crucial aspect for directing the reprogrammed cells toward clinical trials. The CRISPR-Cas9 system has been promising as a tool for correcting gene mutations in maladies including blood disorders and muscular degeneration as well as neurological, cardiovascular, renal, genetic, stem cell, and optical diseases. In this review, we highlight recent developments and utilization of the CRISPR-Cas9 system in correcting or generating gene mutations to create model organisms to develop deeper insights into diseases, rescue normal gene functionality, and curb the progression of a disease. Delivery of CRISPR-components being a pivotal aspect in proving its effectiveness, various proven delivery systems have also been briefly discussed. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ramakrishna, S. | - |
dc.identifier.doi | 10.1016/j.jconrel.2022.02.005 | - |
dc.identifier.scopusid | 2-s2.0-85124672437 | - |
dc.identifier.wosid | 000794134300001 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, v.343, pp.703 - 723 | - |
dc.relation.isPartOf | Journal of Controlled Release | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.volume | 343 | - |
dc.citation.startPage | 703 | - |
dc.citation.endPage | 723 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | Neurology | - |
dc.subject.keywordPlus | Transcription | - |
dc.subject.keywordPlus | current | - |
dc.subject.keywordPlus | Biomedical applications | - |
dc.subject.keywordPlus | Clustered regularly interspaced short palindromic repeat delivery | - |
dc.subject.keywordPlus | Genes mutation | - |
dc.subject.keywordPlus | Immunotherapy | - |
dc.subject.keywordPlus | Neurological disorders | - |
dc.subject.keywordPlus | Palindromic | - |
dc.subject.keywordPlus | Stem-cell | - |
dc.subject.keywordPlus | Therapeutic | - |
dc.subject.keywordPlus | Therapeutic Application | - |
dc.subject.keywordPlus | Stem cells | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | CRISPR delivery | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Neurological disorders | - |
dc.subject.keywordAuthor | Stem cells | - |
dc.subject.keywordAuthor | Therapeutics | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0168365922000803?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.